Vivian Randall W

TL;DR: In this paper, the authors provide pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compound of Formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of Formula (I).

TL;DR: In this article, the authors described compounds of formula (I): or a salt thereof as described in this paper, and provided pharmaceutical compositions comprising a compound of formula, processes for preparing compounds of formulas, intermediates useful for preparing compound of formulas I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of Formula (I).

TL;DR: In this paper, the present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds and therapeutic methods with at least one additional therapeutic agent.

TL;DR: It is demonstrated that upon metabolic activation TGV is a specific, covalent inhibitor of the HCV NS5B polymerase and is mechanistically distinct from other classes of the non-nucleoside inhibitors (NNI) of the viral polymerase.

TL;DR: In this article, the authors provide pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein and intermediates useful for preparing compound disclosed in this paper. But they do not provide any therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed in the paper.